Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Modern molecular diagnostics].

Ugeskrift for laeger·2026
Same author

The effect of the probiotic supplement-ASTARTE™-on the reduction of recurrent urinary tract infection in women aged 18-40 years: protocol for a randomized, double-blind, placebo-controlled study.

Trials·2026
Same author

ClusterVAP: study protocol for multicentre proteomic endotyping of ventilator-associated pneumonia.

BMJ open respiratory research·2026
Same author

Results of bacterial cultivation are infrequently utilized in the treatment of patients hospitalized with severe odontogenic infections - a retrospective cohort study.

Journal of oral microbiology·2025
Same author

Activity of cloxacillin against <i>Cutibacterium acnes</i>: MIC evaluation and utility of gradient test.

Infectious diseases (London, England)·2025
Same author

Can we rely on using penicillin as the first-line treatment of pneumonia in outpatient care?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2025
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Pivmecillinam: past, present, and future.

Niels Frimodt-Möller1, Frederik Boetius Hertz1,2

  • 1Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.

Expert Opinion on Pharmacotherapy
|May 14, 2026
PubMed
Summary
This summary is machine-generated.

Pivmecillinam is an effective oral antibiotic for uncomplicated urinary tract infections (uUTI). Its narrow spectrum and stability make it a valuable option with low resistance in key uropathogens like Escherichia coli.

Keywords:
Mecillinamantibiotic resistancepivmecillinampyelonephritisurinary tract infection

More Related Videos

In Vivo Mouse Model of Spinal Implant Infection
08:03

In Vivo Mouse Model of Spinal Implant Infection

Published on: June 23, 2020

Related Experiment Videos

Last Updated: May 15, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

In Vivo Mouse Model of Spinal Implant Infection
08:03

In Vivo Mouse Model of Spinal Implant Infection

Published on: June 23, 2020

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Urology

Background:

  • Pivmecillinam is an oral prodrug of mecillinam, an aminopenicillin antibiotic.
  • It exhibits activity against major uropathogens and has been a primary treatment for uncomplicated urinary tract infections (uUTI) in Nordic countries for decades.
  • Resistance levels in Escherichia coli remain low, around 5%.

Purpose of the Study:

  • To review the clinical use, pharmacokinetics, pharmacodynamics, and safety of pivmecillinam.
  • To discuss its role in treating uncomplicated urinary tract infections (uUTI) and acute pyelonephritis.
  • To provide insights into dosing recommendations and its potential use in other conditions like bacterial diarrhea.

Main Methods:

  • A literature search was conducted using PubMed between January and February 2026.
  • The review synthesized information on mechanism of action, resistance, pharmacokinetics, pharmacodynamics, adverse effects, and clinical applications.
  • Focus was placed on clinical experience, including optimal dosage and treatment duration.

Main Results:

  • Pivmecillinam is stable against many broad-spectrum beta-lactamases, enhancing its utility as an empiric antibiotic.
  • The primary indication is uUTI, with efficacy also noted in acute pyelonephritis and certain types of bacterial diarrhea.
  • Clinical data supports its use, though optimal dosing and duration are still debated.

Conclusions:

  • Pivmecillinam is a valuable agent for empiric and targeted treatment of UTIs.
  • Its favorable antibacterial spectrum, beta-lactamase stability, minimal microbiome impact, and safety profile support its role.
  • It offers a beneficial option for managing common uropathogen infections.